The gut microbiota profits from its high metabolic potential for generating its own energy, mainly by fermenting dietary non-digestible carbohydrates ([@bib23]). The carbohydrate fermentation end products are gases and organic acids, including lactate and short-chain fatty acids (SCFA) such as acetate, propionate and butyrate ([@bib23]). In humans, butyrate constitutes a major energy source for colonocytes ([@bib14]). Propionate is mainly taken up by the liver, whereas acetate reaches peripheral tissues ([@bib14]). Short-chain fatty acids are considered key metabolic and immune cell regulators ([@bib23]). Acetate and propionate exhibit anti-inflammatory properties in human monocytes and *in vivo* in colitis models ([@bib10]; [@bib21]). In human cancer cells, butyrate and other SCFA affect the cell cycle by inhibiting proliferation and inducing differentiation and cell death ([@bib26]; [@bib2]; [@bib29]). Intracellular mechanisms involved in cell proliferation and cell death (activation of caspases 3 and 7, and decreased histone deacetylase activity), have been extensively evaluated using *in vitro* assays ([@bib2]; [@bib29]). More recently, two G-protein-coupled receptors, free fatty acid receptor 3 (FFA3) and FFA2, also known as GPR41 and GPR43, respectively, have been identified as receptors for SCFA ([@bib5]; [@bib18]). Propionate is considered the most potent endogenous agonist for both FFA3 and FFA2 ([@bib5]; [@bib18]). Free fatty acid receptor 2 expression occurs mainly in immune cells, but also in adipocytes, enterocytes and endocrine cells ([@bib5]; [@bib18]). Free fatty acid receptor 3 exhibits a widespread expression pattern (spleen, lymph nodes, bone marrow, adipose tissue and colon) ([@bib5]; [@bib18]). Lessons from *FFA2* knock-out mice and small-interfering RNA technology, revealed properties of propionate and acetate attributed to their FFA2-binding activity, for example, the resolution of the inflammatory response in a mouse model of colitis ([@bib21]), neutrophil chemotaxis ([@bib33]), glucagon-like peptide-1 secretion ([@bib32]) and pre-adipocyte differentiation ([@bib16]).

Based on the theory that butyrate decreases proliferation and increases apoptosis of colon cancer cell lines ([@bib26]; [@bib29]), a nutritional approach, that is, administering fermentable non-digestible carbohydrates, has been proposed as an adjuvant in the treatment of colon cancer ([@bib24]). Interestingly, fermentable non-digestible carbohydrates might also be relevant to controlling tumour growth outside the gastrointestinal tract. We, and others, have described an oral administration of inulin-type fructans (ITF), which are non-digestible carbohydrates, that decreases the tumour size in liver or mammary cancer mouse models ([@bib31]; [@bib17]). Inulin-type fructans are fermented by saccharolytic bacteria, leading to an increased production of SCFA in the mouse caecum ([@bib6]). As a prebiotic nutrient, ITF change the composition and the activity of the gut microbiota ([@bib12]), and control the host metabolism and immunity (primarily demonstrated in colitis, obesity and diabetes models) ([@bib9]; [@bib7]; [@bib8]). Even so, no mechanistic study investigating ITF systemic anti-tumour effects has been performed so far.

We hypothesised that the increased SCFA production following ITF administration could hinder systemic cancer progression, and this could occur through FFA2 activation. We chose, as a model, murine proB BaF3 cells that ectopically express Bcr-Abl because they can invade and proliferate in the lymphoid organs ([@bib25]; [@bib13]; [@bib3]), such as liver tissue, which actively takes up the SCFA that originates from the gut. Here, we demonstrate *in vivo* that ITF reduces BaF3 cell proliferation, increases propionate in the portal vein and lowers systemic inflammation, and *in vitro* that propionate reduces BaF3 cell proliferation through a cAMP level-dependent pathway and that FFA2 activation alters BaF3 cell growth.

Materials and methods
=====================

Animals
-------

Female BALB/c mice (5-week-old, Charles River, France) were housed with two mice per cage in a 12-h light/dark cycle. Either a saline solution or BaF3 cells (1 × 10^6^ cells in 0.1 ml saline) were injected into the tail vein of the anaesthetised mice. A day after the BaF3 inoculation, half of the mice that were transplanted with BaF3 cells received 0.2 g per day of ITF (Orafti p95, Beneo-Orafti, Oreye, Belgium) in the drinking water. The intake of food and water was recorded every 2 days to monitor the ITF consumption. The mice were killed at an advanced stage of the illness (13 days after the BaF3 inoculation) after anaesthesia with ketamine/xylazine i.p., 100 and 10 mg/kg, respectively. Blood samples, liver, spleen and caecum content were harvested for further analysis. The experiment was approved by the local ethics committee, and the housing conditions were as specified by the Belgian Law of 6 April 2010, on the protection of laboratory animals (Agreement LA 1230314).

Tissue and cells mRNA analyses
------------------------------

Total RNA was isolated from the tissues and the cells using a TriPure Isolation Reagent Kit (Roche Diagnostics, Penzberg, Germany). Complementary DNA was prepared by reverse transcription of 1 *μ*g total RNA using a Reverse Transcription System Kit (Promega, Madison, WI, USA). Quantitative polymerase chain reactions (qPCR) were performed as previously described ([@bib3]). The primer sequences for the targeted genes are detailed in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}.

Gut microbiota analyses
-----------------------

The gut microbiota composition was assessed by 16S rRNA gene analysis using denaturing gradient gel electrophoresis (DGGE) and qPCR, as previously described ([@bib3]). Genomic DNA was extracted from the caecal content using a QIAamp DNA Stool Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer\'s instructions. Full protocols are available online as [Supplementary Methods](#sup1){ref-type="supplementary-material"}.

Biochemical and histological analyses
-------------------------------------

The plasma ℒ-lactate concentration was determined spectrophotometrically by measuring at 340 nm the increase of the NADH-mediated absorbance in the presence of NAD+ and ℒ-lactate dehydrogenase (Roche, Mannheim, Germany) in a basic buffer. A spectrophotometric kit was used to determine the lactate dehydrogenase activity (Diasys, Sopachem, Brussels, Belgium). Plasma cytokines were measured using a customised multiplex kit (Bio-Rad, Nazareth, Belgium) and Luminex technology (Bio-Plex, Bio-Rad). The hepatic triglyceride content was determined using a spectrophotometric kit (Diasys) after lipid extraction with chloroform--methanol (2 : 1) according to Folch\'s method. To measure the hepatic glycogen content, liver tissue was digested in an alkaline medium and, after neutralisation, incubated in the absence or presence of amyloglucosidase. The glucose concentrations were determined for each condition with a spectrophotometric kit (Diasys), and the glycogen content was calculated as the difference in the glucose concentrations plotted to a standard curve. For the histological analysis, the formalin-conserved liver was embedded in paraffin.

Short-chain fatty acids analysis
--------------------------------

Short-chain fatty acids were quantified using ultraperformance liquid chromatography coupled to mass spectrometry (UHPLC-MS) following extraction from serum and subsequent derivatisation. The extraction and derivatisation protocols were performed as described previously for valproic acid ([@bib1]). Briefly, SCFA were extracted from 50 *μ*l of the portal serum with HCl, acetonitrile and KCl. After centrifugation, the upper phase was incubated with potassium carbonate. The derivatisation was performed with 2-bromo-2-acetonaphthone in the presence of 1,4,7,10,13-pentaoxacyclopentadecane and K~2~CO~3~. At the end of the reaction, the liquid phase was recovered and dried under a nitrogen stream. The resulting residue was dissolved in methanol. A 5-*μ*l aliquot was analysed by UHPLC-MS using an LTQ-Orbitrap Mass Spectrometer (ThermoFisher Scientific, Aalst, Belgium) coupled to an Accela UHPLC System (ThermoFisher Scientific). Analyte separation was achieved using a Hypersil Gold aQ (50 × 2.1) column (Thermo Scientific). The mobile phases A and B were composed of acetonitrile--H~2~O--acetic acid 10 : 90 : 0.1 (v/v/v) and acetonitrile-acetic acid 100 : 0.1 (v/v), respectively. The gradient (0.5 ml min^−1^) was designed as follows: 8 min of 90% A; a transition from 90% A to 100% B linearly over 6 min; followed by 3 min at 100% B and a subsequent re-equilibration at 90% A. We performed MS analysis in the positive mode with an APCI ionisation source. Acetate, propionate and butyrate were quantified using valproate as an internal standard, and the calibration curves were prepared from pure standards diluted in water. The nature of the analytes was confirmed by their exact mass, MS2 fragmentation and co-elution with pure standards. Additionally, to reduce the acetate contamination, UltraPure Water (Cayman Chemical, Tallinn, Estonia) and HPLC-grade acetonitrile (VWR, Leuven, Belgium) were purified by SPE on StratoSpheres columns (PL-HCO3 MP-resin, Varian, Agilent Technologies, Santa Clara, CA, USA).

Cell culture and chemicals
--------------------------

The BaF3 cell line transfected with Bcr-Abl was a gift from Dr K Bhalla (MCG Cancer Centre, Medical College of Georgia, Augusta, GA, USA). The BaF3 cells were maintained in RPMI medium 1640 supplemented with 10% foetal bovine serum (PAA clone, PAA, Pasching, Austria), streptomycin 100 *μ*g ml^−1^, penicillin 100 IU ml^−1^ and 1% of non-essential amino acids solution (Gibco, Inchinnan, Scotland) at 37 °C in humidified 5% CO~2~. The generation of these cells is described in detail elsewhere ([@bib13]). The human histiocytic lymphoma U937 ([@bib28]) and lymphoblast K562 cells were maintained in the same conditions, except for the non-essential amino acids solution.

All chemicals were purchased from Sigma-Aldrich, Saint Louis, MO, USA, except the synthetic FFA2 agonist (4-chloro-*α*-(1-methyl ethyl)-*N*-2-thiazolyl-benzeneacetamide) (CMTB) ([@bib34]) (Ambinter, Paris, France).

Cell proliferation (MTT, manual counting, BrdU)
-----------------------------------------------

The cell growth assay is based on metabolically active cells cleaving yellow thiazolyl blue tetrazolium bromide (MTT) to form purple formazan crystals. The formazan absorbance was measured at 570 nm, from which a background value, measured at 650 nm, was subtracted. Cell proliferation is expressed as a percentage of the value obtained for cells incubated with the vehicle (medium, PBS or DMSO, final concentration between 0.1 and 0.2%). For manual counting, intact cells (determined by exclusion of erythrosine) were counted under a microscope in a Bürker cell. The bromodeoxyuridine incorporation assay was performed following the manufacturer\'s instructions (Cell Proliferation ELISA, BrdU colorimetric, Roche, Mannheim, Germany). All of the assays were performed in medium containing 10% foetal bovine serum. Complete protocols are available online as [Supplementary Methods](#sup1){ref-type="supplementary-material"}.

Statistical analysis
--------------------

The results are expressed as the mean±s.e.m. Student\'s *t*-test, one-way ANOVA with Tukey *post hoc* test and two-way ANOVA with Bonferroni *post hoc* test were used for statistical analysis. *P*\<0.05 was considered statistically significant (Graph-Pad Prism Software, San Diego, CA, USA).

Results
=======

Inulin-type fructans administration decreases hepatic infiltration of BaF3 cells and systemic inflammation in mice
------------------------------------------------------------------------------------------------------------------

BaF3 cells were transplanted into mice resulting in an aggressive malignancy that mimicked acute leukaemia and was characterised by an accumulation of BaF3 cells in the liver and spleen. The liver and spleen weights increased in the mice transplanted with BaF3 cells (BaF3 mice), in accordance with the fact that BaF3 cells infiltrate these organs ([Figure 1A](#fig1){ref-type="fig"}). Intriguingly, ITF administration impaired the liver weight gain induced by BaF3 cells without any significant effect on the spleen weight. Because Bcr-Abl is a chimeric protein, solely and constitutively expressed in BaF3 cells, it is a valuable marker of BaF3 cell presence. The reduced hepatic expression of Bcr-Abl in BaF3-ITF mice compared with BaF3 mice reflects a lower infiltration of the hepatic parenchyma by the BaF3 cells ([Figure 1B](#fig1){ref-type="fig"}) as suggested by histological observation ([Supplementary Figure 1A](#sup1){ref-type="supplementary-material"}). Hepatic glycogen and triglyceride contents cannot account for the difference in liver weight because they were similar between BaF3 and BaF3-ITF mice ([Supplementary Figures 1B and C](#sup1){ref-type="supplementary-material"}). Concordantly to the spleen weight, splenic Bcr-Abl expression was not significantly modified by ITF administration ([Figure 1B](#fig1){ref-type="fig"}, *P*=0.21). The glycolysis pathway becomes predominant in malignant cell lines and tumours and generates lactacte as an end product, whereas lactate dehydrogenase activity in the blood reflects a general cellular turnover and is a negative prognostic factor of leukaemia progression ([@bib22]; [@bib27]). Accordingly, plasma ℒ-lactate and plasma lactate dehydrogenase activity were both increased in the presence of the BaF3 tumour, whereas ITF administration decreased these levels ([Figure 1C and D](#fig1){ref-type="fig"}). Of note, there were no changes in water or food intake due to the ITF administration (data not shown).

Given that both cancer cell progression and ITF treatment are able to modulate immunity, we measured a panel of cytokines in the plasma. Plasma interleukin 4 (IL-4), interleukin 6 (IL-6), interleukin 10 (IL-10), granulocyte colony-stimulating factor (G-CSF), interleukin 8 (IL-8), monocyte chemo-attractant protein 1 (MCP-1) and RANTES were significantly increased in the BaF3 mice ([Figure 1E--K](#fig1){ref-type="fig"}). Inulin-type fructans administration to BaF3 mice decreased IL-4, IL-8 and MCP-1 levels ([Figure 1E, I](#fig1){ref-type="fig"}) with no significant effect on IL-10, G-CSF and RANTES levels ([Figure 1G, H](#fig1){ref-type="fig"}). Interleukin 6 is decreased by ITF treatment, and this is significant by Student\'s *t*-test (*P*=0.04). Interferon gamma (IFN*γ*) tends to be decreased by ITF feeding (*P*=0.05, Student\'s *t*-test) ([Figure 1L](#fig1){ref-type="fig"}).

Inulin-type fructans administration modifies gut microbiota composition and increases propionate in the portal vein
-------------------------------------------------------------------------------------------------------------------

We hypothesised that ITF administration reduced BaF3 cell infiltration and lowered systemic inflammation through gut microbiota modulation. The changes in the gut microbial composition were assessed using DGGE and qPCR of the 16S rRNA gene sequences for total bacteria, *Lactobacillus* spp., *Bifidobacterium* spp. (two Gram-positive genera known for anti-inflammatory properties ([@bib20])) and *Bacteroides* spp. (a predominant Gram-negative genus). The DGGE fingerprints for total bacteria revealed three separate clusters, corresponding to each treatment ([Figure 2A](#fig2){ref-type="fig"}). The dendrogram of the DGGE fingerprints showed that the BaF3-ITF mouse fingerprints are closer to those from the control mice compared with the BaF3 mouse fingerprints. Total bacteria and the Gram-negative *Bacteroides* were modified by neither the BaF3 transplantation nor the ITF administration ([Figure 2B](#fig2){ref-type="fig"}). Lactobacilli levels were reduced in the BaF3 mice *vs* the control mice without any impact from the ITF supplementation. Notably, the number of bifidobacteria was below the quantification limit in the mice strain used in this study, that is, BALB/c mice.

The caecal content weight tended to decrease in BaF3 mice (not significant in one-way ANOVA, but *P*=0.003 by Student\'s *t*-test) ([Figure 2C](#fig2){ref-type="fig"}). We can reasonably suggest that the decreased caecal content weight in BaF3 mice results from the reduced food intake observed during the last 2 days of the experiment (food intake from day 11 to day 13: CT: 9.62±0.51; BaF3: 7.02±0.37g\* BaF3-ITF: 7.07±0.31g\* *n*=4, \**P*\<0.05 *vs* CT). However, the caecal content weight was increased in BaF3-ITF mice, even if these mice ate the same amount of food than BaF3 mice. This increase in the caecal content weight reflects the fermentation that occurs upon ITF feeding. The fermentation hypothesis is also supported by the increased caecal tissue weight, only observed in BaF3-ITF mice ([Figure 2C](#fig2){ref-type="fig"}). Because we hypothesised that increased SCFA levels could explain the effect of the ITF treatment on cancer progression, we set up a method to quantify the levels of acetate, propionate and butyrate in the portal serum. BaF3 mice tend to exhibit a decreased level of serum propionate and butyrate (*P*=0.02 and 0.05, respectively, Student\'s *t*-test). The ITF supplementation did not modify the acetate and butyrate levels, but did induce a two-fold increase of propionate levels ([Figure 2D--F](#fig2){ref-type="fig"}).

Short-chain fatty acids decrease BaF3 cell proliferation *in vitro*
-------------------------------------------------------------------

As typical metabolites of ITF fermentation, SCFA are potentially suitable candidates that could account for the effects of ITF on BaF3 cell growth. Indeed, BaF3 cells incubation in the presence of SCFA resulted in a time- and dose-dependent decrease in cell proliferation, as shown by a MTT assay ([Figure 3A--C](#fig3){ref-type="fig"}). Notably, SCFA at 10 mℳ did not modify the pH of the medium. Amongst the SCFA, acetate was less potent than propionate or butyrate. 0.2 mℳ propionate slightly but significantly reduced BaF3 cell growth (after 48 h of incubation, control: 100±1% propionate 0,2 mℳ: 95±1% of control proliferation; *n*=3 in triplicate, *P*=0.0032). Given that *in vivo* ITF increased propionate (but not acetate or butyrate) and reduced BaF3 cell proliferation, we focused our *in vitro* studies on the anti-proliferative effect of propionate. Shorter-term incubations, and, therefore, supra-physiological doses, were used to study the potential mechanisms of propionate. BrdU incorporation, reflecting the DNA synthesis, was decreased after 8 and 24 h of incubation in the presence of 2 and 10 mℳ propionate ([Figure 3D](#fig3){ref-type="fig"}). These results were confirmed by counting living BaF3 cells incubated in the presence of 2 mℳ propionate for 24, 48 or 72 h ([Figure 3E](#fig3){ref-type="fig"}).

Propionate reduces BaF3 cell growth through a cAMP level-dependent pathway
--------------------------------------------------------------------------

Propionate is one of the most potent endogenous FFA2 ligands and FFA2 is highly expressed by BaF3 cells ([@bib21]). Therefore, we next wanted to determine if a G-protein-coupled receptor pathway (potentially FFA2) was involved in the anti-proliferative effect of propionate. FFA2 displays a dual coupling through Gi and Gq protein families ([@bib5]; [@bib18]). Therefore, BaF3 cells were incubated with U73122, a phospholipase C (PLC) inhibitor. PLC blockade did not blunt the propionate-induced cell growth arrest ([Figure 3F](#fig3){ref-type="fig"}; raw data in [Supplementary Figure 2](#sup1){ref-type="supplementary-material"}). Gi protein inhibits adenylyl cyclase and subsequently reduces cAMP. Therefore, we next investigated if cAMP levels have a role in the anti-proliferative effect of propionate. DibutyrylcAMP, a cAMP analogue, or 3-isobutyl-1-methylxanthine (IBMX), an inhibitor of phosphodiesterases, slightly reduced the anti-proliferative action of propionate ([Figure 3F](#fig3){ref-type="fig"}; raw data in [Supplementary Figure 2](#sup1){ref-type="supplementary-material"}). Furthermore, isoproterenol, a *β*-adrenoceptor agonist that, among other properties, increases cAMP, also slightly reduced the anti-proliferative effect of propionate ([Supplementary Figure 2](#sup1){ref-type="supplementary-material"}). Overall, these data suggest that the anti-proliferative effect of propionate is partially dependent on the cAMP level.

Free fatty acid receptor 2 activation decreases mouse and human cell proliferation *in vitro*
---------------------------------------------------------------------------------------------

Finally, we wanted to know whether FFA2 activation is actually able to reduce BaF3 cell growth. To this end, we used CMTB, a potent synthetic FFA2 agonist ([@bib34]), and found that it reduced cell proliferation in a time- and dose-dependent manner (MTT and BrdU assays) ([Figure 4A and B](#fig4){ref-type="fig"}). These results were confirmed by microscopic observation after the CMTB treatment ([Figure 4C](#fig4){ref-type="fig"}). Furthermore, U73122, dibutyrylcAMP, IBMX and isoproterenol inhibited CMTB-induced cell growth arrest, suggesting that both cAMP- and PLC-dependent pathways are involved in the anti-proliferative effect of CMTB ([Supplementary Figure 3](#sup1){ref-type="supplementary-material"}).

To support the role of FFA2 in CMTB and propionate effects, we tested their impact on Lewis lung carcinoma (LLC) cells, a cell line that expressed low levels of FFA2 ([Supplementary Figure 4A](#sup1){ref-type="supplementary-material"}). BaF3 cells were more sensitive to the anti-proliferative action of CMTB and propionate than LLC cells that were almost completely resistant to both treatments, after a 24-h incubation ([Supplementary Figure 4B and C](#sup1){ref-type="supplementary-material"}). Remarkably, LLC and BaF3 cells were similarly sensitive to doxorubicin, a classical chemotherapeutic agent ([Supplementary Figure 4D](#sup1){ref-type="supplementary-material"}) ([@bib4]). We can thus reject the hypothesis that LLC cells are generally resistant to any kind of anti-proliferative treatment.

To further extend the concept of FFA2 as a new cancer therapeutic target, we studied the effect of CMTB on two human cancer cell lines, U937 cells and K562 cells. CMTB reduced the growth of both cell lines. The U937 cells, which express a 25-fold higher level of the FFA2 transcript as compared with the K562 cells, are more sensitive to CMTB treatment ([Figure 4D and E](#fig4){ref-type="fig"}).

Discussion
==========

In this study, we demonstrate in an acute leukaemia mouse model that dietary ITF administration reduces cancer cell infiltration into the liver and reduces the inflammation associated with cancer progression. *In vitro*, we demonstrated that the anti-proliferative effect of propionate was partially cAMP level-dependent, and that FFA2 activation altered cancer cell proliferation. These results support the idea of a role for gut microbiota in the control of systemic cancer.

The anti-inflammatory effect of dietary ITF was demonstrated in pathological conditions, such as obesity, diabetes or intestinal inflammation ([@bib9]; [@bib7]; [@bib8]) and this effect was related to the microbial changes induced by ITF feeding, namely to an increase in bifidobacteria and lactobacilli ([@bib20]). The ITF fermentation, reflected by the increased caecal content and tissue weights in BaF3-ITF mice, is accompanied by changes in the total gut microbiota composition, without changing lactobacilli and bifidobacteria levels. Therefore, at this stage, we cannot attribute the anti-inflammatory effect of ITF to the changes in the level of lactic acid bacteria, as suggested in other models.

The gut microbiota could influence BaF3 cell progression by changing its metabolome. We hypothesised that a gut microbiota-derived metabolite, that is increased upon ITF treatment and specifically targets liver tissue, could mediate a protective effect. Propionate fulfills all of these requirements because it is increased in the portal vein of ITF-fed rats ([@bib11]) and is mostly taken up by the liver ([@bib14]). In the present *in vivo* study, propionate levels were increased in the portal blood of the BaF3-ITF mice. Of note, propionate and butyrate levels tended to be decreased upon cancer. This could be explained by the altered gut microbiota composition or by the decreased food intake observed at the end of the treatment, which could have lessened the substrate supply.

Corroborating the *in vivo* study, *in vitro* studies showed an anti-proliferative effect of propionate on BaF3 cells. Therefore, we suggest that propionate is, amongst the SCFA, the most likely mediator of the ITF anti-tumour effect. We can speculate that propionate uptake by the liver explains why ITF has an impact on BaF3 cell progression in the liver and not in the spleen.

In human colon cancer cells and neutrophils, the anti-proliferative capacity of SCFA has been associated with the SCFA ability to inhibit histone deacetylase activity ([@bib15]; [@bib2]). Butyrate was the most powerful inhibitor, whereas propionate demonstrated an intermediate profile. Acetate did not influence the histone deacetylase activity ([@bib15]; [@bib2]). In our *in vitro* experiments, both acetate and propionate reduce BaF3 cell proliferation. This led us to hypothesise that targets other than histone deacetylases might be involved in the *in vitro* anti-proliferative effect of SCFA, namely FFA2 and FFA3. Quantitative real-time PCR revealed that FFA3 expression in the BaF3 cells was approximately 100-fold lower than FFA2 expression (data not shown). Therefore, we focused on the potential implication of FFA2. In view of the comparison of cell lines with different level of expression of FFA2 (LLC and BaF3 cells), we postulate that FFA2 might be involved in the anti-proliferative action of propionate. Free fatty acid receptor 2 can couple with the Gi and Gq pathways ([@bib5]; [@bib18]). Blocking the Gq-PLC pathway through a PLC inhibitor did not counteract the anti-proliferative effect of propionate. Mimicking an increase in cAMP level (by dibutyrylcAMP) and indirectly modifying cAMP level (by IBMX or isoproterenol) significantly, but only slightly, reduces the anti-proliferative effect of propionate. Therefore, we propose that the anti-proliferative activity of propionate could be PLC-independent and partially cAMP level-dependent. Phenylacetamide derivatives, such as CMTB, have been recently described as FFA2 agonists and are inactive against a panel of GPCRs (included FFA3) at concentrations of up to 30 *μ*ℳ ([@bib19]; [@bib34]). Here, we establish that FFA2 activation by CMTB reduces BaF3 cell growth through PLC- and cAMP level-dependent pathways. Importantly, evidence from pharmacological studies suggests that the signalling pathways downstream of FFA2 are differentially activated by synthetic and endogenous ligands ([@bib19]). In fact, molecular modelling analysis revealed that CMTB and endogenous ligands do not bind to the same site, and this could be related to the fact that CMTB and propionate differentially activate the Gi and Gq pathways. Indeed, CMTB analogues equally activate Gq and Gi pathways, whereas propionate is much more potent on the Gi than the Gq pathway ([@bib19]). Additional work is needed to evaluate the molecular characteristics of FFA2 at the protein level in FFA2-expressing cancer cells, before really evaluating the contribution of the binding of propionate to FFA2 in its anti-proliferative activity.

Finally, using human leukaemic cell lines, we have extended the concept of FFA2 activation as a tumour-suppressive therapy. [@bib30]) recently reported that increasing the FFA2 expression in human colon cancer cells by plasmid transfection sensitises them to the action of propionate. Our results suggest that FFA2 is of therapeutic interest for the treatment of different hematopoietic cancers.

In conclusion, both *in vivo* and *in vitro* approaches support the therapeutic potential of nutrients targeting the gut microbiota in the control of leukaemic disease. We propose that propionate production could be one of the gut microbial functions responsible for the anti-tumour effect of prebiotic nutrients. Furthermore, our data support the therapeutic interest in the pharmacological activation of FFA2 to control cancer cell proliferation.
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![Inulin-type fructans treatment decreases the hepatic infiltration of the BaF3 cells and systemic inflammation in mice. (**A**) Liver and spleen weights of the control mice (CT), mice transplanted with BaF3 cells (BaF3) and mice transplanted with BaF3 cells and fed ITF (BaF3-ITF). (**B**) Bcr-Abl mRNA levels, ND: not detected. (**C**, **D**) Plasma ℒ-lactate and lactate dehydrogenase (LDH) activity. (**E**--**L**) Plasma levels of IL-4, IL-6, IL-10, G-CSF, IL-8, MCP-1, RANTES and IFN*γ*. *n*=7--8. \**P*\<0.05 *vs* CT, ^§^*P*\<0.05 *vs* BaF3.](bjc2012409f1){#fig1}

![Inulin-type fructans treatment modifies the gut microbiota composition and increases the propionate concentration in the portal vein. (**A**) Denaturing gradient gel electrophoresis (DGGE) profiles of the bacterial DNA isolated from the caecal content. Cross for the CT mice; closed circle for the BaF3 mice; and open circle for the BaF3-ITF mice. (**B**) Levels of total bacteria, *Lactobacillus* spp. and *Bacteroides* spp. CFU: colony-forming unit. (**C**) Caecal tissue and caecal content weights. (**D**--**F**) Serum acetate, propionate and butyrate concentrations in the portal vein. *n*=7--8. \**P*\<0.05 *vs* CT, ^§^*P*\<0.05 *vs* BaF3.](bjc2012409f2){#fig2}

![Short-chain fatty acids decrease BaF3 cell proliferation *in vitro*. (**A**--**C**) BaF3 cells were incubated in the absence or presence of acetate, propionate, butyrate for 24, 48 and 72 h before performing the MTT assay. (**D**) BrdU incorporation after 8 or 24 h incubation in the absence or presence of propionate. (**E**) Manual counting of BaF3 cells after 24, 48 and 72 h in the absence or presence of 2 mℳ propionate. (**F**) BaF3 cells were pre-incubated in the absence or presence of the indicated drug (U73122, 2 *μ*ℳ, 1 h; dbcAMP 1 mℳ, 30 min; IBMX, 316 *μ*ℳ, 1 h) and then incubated in the absence or presence of propionate for 24 h. Data are expressed as a percentage of the control performed for each pharmacological condition in the absence of propionate. MTT assay. The graphs represent data obtained from at least three independent experiments performed in triplicate. \**P*\<0.05 *vs* the control. For F, each set of data was analysed by two-way ANOVA with Bonferroni *post hoc* test taking into account control values.](bjc2012409f3){#fig3}

![Free fatty acid receptor 2 (FFA2) activation decreases the proliferation of BaF3 cells *in vitro.* (**A**) BaF3 cells were incubated in the absence or presence of CMTB for 24, 48 and 72 h before performing MTT assay. (**B**) BrdU incorporation after 8 or 24 h incubation in the absence or presence of CMTB. \**P*\<0.05 *vs* the control. (**C**) Microscopic pictures of BaF3 cells incubated in the absence or presence of CMTB. Scale bar=100 *μ*ℳ. (**D**) Free fatty acid receptor 2 (FFA2) mRNA levels in U937 and K562 cells. \**P*\<0.05 *vs* U937. *n*=1 in triplicate. (**E**) U937 and K562 cells were incubated in the absence or presence of CMTB for 24 h. MTT assay. \**P*\<0.05 *vs* U937. The MTT and BrdU assays graphs represent data obtained from at least three independent experiments performed in triplicate.](bjc2012409f4){#fig4}

[^1]: These authors contributed equally to this work.
